In this study, we performed deep proteomics and phosphoproteomics profiling of 45 HER2+ breast cancer tumors prior to the start of neo-adjuvant treatment with PTC-Ptz to identify molecular signatures predictive of treatment response. This evidence concerns the gene ERBB2 and breast cancer.